Related Experiment Videos
How much do novel antipsychotics benefit the patients?
1Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Vienna, Austria.
International Clinical Psychopharmacology
|August 5, 1998
Summary
Novel antipsychotics like sertindole improve medication adherence in schizophrenia patients by reducing negative symptoms and extrapyramidal symptoms (EPS). This leads to better long-term outcomes and fewer relapses for individuals with schizophrenia.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Schizophrenia pharmacotherapy faces challenges with patient compliance.
- Conventional antipsychotics often fail to address negative symptoms and can cause extrapyramidal symptoms (EPS), worsening patient condition and adherence.
Observation:
- Novel antipsychotics, specifically atypical agents like sertindole, demonstrate efficacy against both positive and negative symptoms of schizophrenia.
- These newer medications do not induce EPS and preserve cognitive function.
Findings:
- Sertindole shows potential in improving patient compliance due to its favorable side effect profile and effectiveness.
- Clinical and postmarketing data suggest sertindole benefits patients, particularly those in their first episode of illness.
Implications:
- Prescribing novel antipsychotics like sertindole to first-episode schizophrenia patients may enhance long-term adherence.
- Improved compliance can lead to sustained treatment, reduced relapse rates, and better overall management of schizophrenia.